Progresses in Treating Agitation: A Major Clinical Challenge in Alzheimer’s Disease

Expert Opinion on Pharmacotherapy - United Kingdom
doi 10.1517/14656566.2015.1092520
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

The Neurochemistry of Agitation in Alzheimer’s Disease: A Systematic Review

Ageing Research Reviews
BiochemistryAgingNeurologyMolecular BiologyBiotechnology
2018English

Plasma Biomarkers Are Associated With Agitation and Regional Brain Atrophy in Alzheimer’s Disease

Scientific Reports
Multidisciplinary
2017English

Clinical Experience of Memantine in Alzheimer’s Disease

European Neurological Review
Neurology
2008English

Depressive Symptoms in Clinical and Incipient Alzheimer’s Disease

Neurodegenerative disease management
MedicineNeurology
2013English

The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer’s Disease

Frontiers in Pharmacology
Pharmacology
2019English

Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials

Neurotherapeutics
NeurologyPharmacology
2016English

Potential of Antihypertensive Drugs for Preventing and Treating Alzheimer’s Disease

Expert Review of Clinical Pharmacology
MedicineToxicologyPharmaceuticsPharmacology
2008English

Chiral Metallohelical Complexes Enantioselectively Target Amyloid Β for Treating Alzheimer’s Disease

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2014English

Does Psychomotor Agitation in Major Depressive Episodes Indicate Bipolarity?

European Archives of Psychiatry and Clinical Neuroscience
MedicinePsychiatryMental HealthBiological PsychiatryPharmacology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy